Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China

Fang Lei,1-3,8* Ye-Mao Liu,2,3* Feng Zhou,3,4 Juan-Juan Qin,2,3* Peng Zhang,3,4 Lihua Zhu,2,3* Xiao-Jing Zhang,2,3 Jingjing Cai,1 Lijin Lin,3,6 Shan Ouyang,3,6 Xiaoming Wang,3,6 Chengzhang Yang,2,3* Xu Cheng,2,3* Weifang Liu,3,6 Haomiao Li,2,3* Jingjing Cai,5 Lijin Lin,3,6 Pengcheng Luo,10 Shouzhi Fu,11 Jihui Zhou,12 Ping Ye,13 Bing Xiao,14 Weiming Mao,15 Liming Liu,16 Youqin Yan,17 Ling Liu,18 Guohua Chen,19 Hongliang Li,2-4,6 Xiaodong Huang,20 Bing-Hong Zhang,21* and Yufeng Yuan1

BACKGROUND AND AIMS: Coronavirus disease 2019 (COVID-19) is a new infectious disease. To reveal the hepatic injury related to this disease and its clinical significance, we conducted a multicenter retrospective cohort study that included 5,771 adult patients with COVID-19 pneumonia in Hubei Province.

APPROACH AND RESULTS: We reported the distributional and temporal patterns of liver injury indicators in these patients and determined their associated factors and death risk. Longitudinal liver function tests were retrospectively analyzed and correlated with the risk factors and death. Liver injury dynamic patterns differed in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBIL). AST elevated first, followed by ALT, in severe patients. ALP modestly increased during hospitalization and largely remained in the normal range. The fluctuation in TBIL levels was mild in the non-severe and the severe groups. AST abnormality was associated with the highest mortality risk compared with the other indicators of liver injury during hospitalization. Common factors associated with elevated liver injury indicators were lymphocyte count decrease, neutrophil count increase, and male gender.

CONCLUSION: The dynamic patterns of liver injury indicators and their potential risk factors may provide an important explanation for the COVID-19-associated liver injury. Because elevated liver injury indicators, particularly AST, are strongly associated with the mortality risk, our study indicates that these parameters should be monitored during hospitalization. (Hepatology 2020;72:389-398).

Coronavirus disease 2019 (COVID-19) is a viral respiratory illness caused by a novel coronavirus. COVID-19 is highly contagious, with more than 2.3 million cases and nearly 163,000 deaths worldwide on April 21, 2020.1,2 The targeting organs of this coronavirus are believed to be the lungs and airways. However, patients often have evidence of damage to other organs, which significantly increases their mortality.3,4 The pathophysiological foundation of multiorgan damage may be associated with organ-specific immune response to disseminated coronavirus or secondary to hypoxemia, systemic cytokine storm, and medication.5 In an attempt to determine the distributional and temporal patterns of liver injury in patients with COVID-19 with a focus on clinical significance and determinants of this change,

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; CoV-2, coronavirus 2; COVID-19, coronavirus disease 2019; CT, computed tomography; DIC, disseminated intravascular coagulation; IQR, interquartile range; SARS, severe acute respiratory syndrome; TBIL, total bilirubin; ULN, upper limit of normal.

Received April 11, 2020; accepted April 28, 2020.

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.31301/suppinfo.

This study was supported by a grant from the National Key Research and Development Program of China (2020YFC0845500 to Y.Y.).

*These authors contributed equally to this work.

© 2020 by the American Association for the Study of Liver Diseases.

View this article online at wileyonlinelibrary.com.

DOI 10.1002/hep.31301

Potential conflict of interest: Nothing to report.
we conducted a multicenter retrospective cohort study that included 5,771 patients in Hubei Province.

Methods

STUDY DESIGN AND PARTICIPANTS

In this multicenter retrospective cohort study, patients with COVID-19 were admitted to the following 10 hospitals that were designated to treat patients with COVID-19: Renmin Hospital of Wuhan University, Thunder Mountain Hospital, Wuhan Ninth Hospital, Huanggang Central Hospital, Zhongnan Hospital of Wuhan University, Wuhan Central Hospital, Wuhan Third Hospital, Wuhan Seventh Hospital, Wuhan First Hospital, and Central Hospital of Enshi Tujia and Miao Autonomous Prefecture. A total of 7,029 adult patients admitted to hospitals from December 30, 2019, to March 8, 2020, were enrolled in the study. Exclusion criteria, which applied to 1,258 patients, were as follows: age younger than 18 or older than 75 years; pregnancy; severe medical conditions, including liver cirrhosis (10 cases [Supporting Table S3]), chronic renal dysfunction (above chronic kidney disease stage 3 [CKD 3]), leukemia, cancer, acquired immune deficiency syndrome, acute myocardial infarction during hospitalization, acute pulmonary embolism (due to a long-term pulmonary embolism disease history, long-term bed rest, and coagulopathy), stroke, and acute pancreatitis; or transfer to other hospitals (Supporting Figure S1).

Chest computed tomography (CT) or throat-swab specimens were obtained from all patients upon admission. COVID-19 was diagnosed by clinical manifestations, chest CT, or real-time PCR according to World Health Organization (WHO) interim guidance and
the New Coronavirus Pneumonia Prevention and Control Program (5th edition) published by the National Health Commission of China. At the time of admission, patients with fever or suspected respiratory infection, plus one of the following clinical manifestations including respiratory rate greater than 30 breaths per minute, severe respiratory distress, or oxygen saturation less than 93% on room air, were classified as severe cases.\(^6\) Staging of COVID-19 and evaluation of organ damage were conducted by a team of physicians. This study was approved by the central institutional ethics committee and ratified by each hospital. A waiver of the requirement for documentation of informed consent was granted for analyzing existing data without interfering with patient treatment.

**PROCEDURES AND COMPLICATION EVALUATION**

The demographic, clinical characteristics, medical history, laboratory tests, radiological reports, therapeutic intervention, and outcome data were obtained from patients’ electronic medical records. Clinical symptoms, including fever, cough, fatigue, dyspnea and comorbidities, were extracted. The laboratory examination included a complete blood count, C-reactive protein, procalcitonin, D-dimer, and serum biochemical tests for liver, kidney, heart, and coagulation dysfunction. Medical history consisted of coexistence of chronic obstructive pulmonary disease, type 2 diabetes mellitus (T2DM), hypertension, coronary heart disease, cerebrovascular disease, chronic liver disease, CKD, cancer, and autoimmune diseases. The unilateral and bilateral lesions in chest CT scan images were recorded and analyzed. Personal identification information (e.g., name, ID) of the study subjects was anonymized and replaced with a coding system before data extraction. Data were reviewed and confirmed by experienced physicians and double-checked to ensure accuracy.

Acute lung injury, acute respiratory distress syndrome, and septic shock were defined according to the WHO interim guideline for “clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected.”\(^4\) Acute kidney injury was defined as an elevation in serum creatinine level ≥ 26.5 μmol/L within 48 hours.\(^7\) Acute liver injury was defined as the levels of serum alanine aminotransferase (ALT) above 3-fold of the upper limit of normal (ULN). Increase in liver enzyme levels was defined as the levels of serum liver enzyme above the ULN. Cardiac injury was defined as the serum level of cardiac troponin I/T or hypersensitive troponin I/T above the ULN.\(^8\) Clinical disseminated intravascular coagulation (DIC) was defined according to the International Society on Thrombosis and Haemostasis criteria for diagnosing DIC.\(^9\) The primary endpoint was recorded and evaluated in this longitudinal cohort, which was 28-day all-cause death. Data were
reviewed and confirmed by two certified physicians to ensure accuracy.

**STATISTICAL ANALYSIS**

Categorical variables were presented as frequency. Continuous variables were described as median (interquartile range [IQR]). Means for continuous variables were compared using independent group Student t tests when the data were normally distributed; otherwise, the Mann-Whitney U test was used. Proportions for categorical variables were compared using the chi-square test. Proportions for categorical variables were compared using the chi-square test or Fisher exact test. Distribution of highest liver enzyme levels (e.g., ALT, aspartate aminotransferase [AST], alkaline phosphatase [ALP], and total bilirubin [TBIL]) by the severity of COVID-19 was presented using kernel density estimation. Dynamic changes of liver enzyme levels by the severity of COVID-19 were presented using locally weighted scatterplot smoothing (LOESS). Site was modeled as a random effect in the mixed-effect Cox model. The mixed-effect Cox proportional hazard regression models were used to investigate the relationship of liver enzyme levels with all-cause mortality among patients. The mixed-effect Cox models were adjusted for age, gender, and coexisting chronic diseases, including hypertension, coronary artery disease, cerebrovascular disease, T2DM, and CKD. Ordinal logistic regression analysis was applied to evaluate the association of baseline characteristics and medications that happened before peaking of liver enzymes with the peak levels of in-hospital liver enzymes in the longitudinal cohort, in whom the liver function markers were trichotomized. The parallel lines assumption of the model was also tested and met. The P values were two-sided, and an alpha level of 0.05 was used to define statistical significance. All analyses were conducted using R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria) or SPSS version 23.0 (IBM, Armonk, NY).

**Results**

**PATIENT POPULATION**

The selected baseline liver characteristics of the enrolled patients are given in Table 1. A total of 5,771 adult patients with COVID-19 were included in the analysis. The median age was 56 (IQR, 43–65 years), and 2,724 (47.2%) were male (Supporting Tables S1 and S2). Among these patients, 4,585 (79.4%) were non-severe cases and 1,186 (20.6%) were classified as severe cases. A total of 81 (1.4%) patients reported chronic liver disease. Among these patients, 4 recorded fatty liver diseases and 77 viral hepatitis (Supporting Table S3). The median day for acute liver injury (ALT > 3 ULN) occurred at day 17 (IQR, 13–23) after symptom onset (Fig. 1).

| TABLE 1. Baseline Liver Function of Study Patients |
|-------------------------------------------------|
| **Parameters**                                  | **Total (n = 5,771)** | **Non-severe Patients (n = 4,585)** | **Severe Patients (n = 1,186)** | **P Value** |
| **Clinical Characteristics**                    |                      |                                      |                                    |             |
| Age, median (IQR), years                        | 56 (43-65)           | 55 (42-64)                           | 59 (48-66)                         | <0.001      |
| Male gender, n (%)                              | 2,724 (47.2%)        | 2,068 (45.1%)                       | 656 (55.3%)                        | <0.001      |
| Chronic liver disease, n (%)                    | 81 (1.4%)            | 56 (1.2%)                           | 25 (2.1%)                          | 0.030       |
| **Laboratory Examination**                      |                      |                                      |                                    |             |
| ALT, median (IQR), U/L                          | 24.0 (15.1-39.0)     | 23.0 (15.0-38.0)                    | 26.0 (17.0-45.0)                   | <0.001      |
| AST, median (IQR), U/L                          | 24.0 (17.0-35.0)     | 22.0 (17.0-31.0)                    | 31.0 (21.0-46.0)                   | <0.001      |
| ALP, median (IQR), U/L                          | 64.0 (51.0-83.0)     | 65.0 (51.0-83.0)                    | 63.0 (50.0-84.0)                   | 0.630       |
| ALB, median (IQR), g/L                          | 37.5 (34.2-40.7)     | 38.0 (34.9-41.1)                    | 35.7 (32.2-38.9)                   | <0.001      |
| GLB, median (IQR), g/L                          | 27.2 (24.2-30.4)     | 27.0 (24.0-30.0)                    | 27.8 (24.9-31.5)                   | <0.001      |
| A/G ratio, median (IQR)                         | 1.4 (1.2-1.6)        | 1.4 (1.2-1.6)                       | 1.3 (1.1-1.5)                      | <0.001      |
| TBIL, median (IQR), μmol/L                      | 10.4 (7.9-14.1)      | 10.3 (7.9-14.0)                     | 10.6 (7.9-15.0)                    | 0.053       |
| Direct bilirubin, median (IQR), μmol/L          | 3.0 (2.1-4.4)        | 2.9 (2.0-4.2)                       | 3.3 (2.2-5.2)                      | <0.001      |
| Indirect bilirubin, median (IQR), μmol/L        | 7.4 (5.2-10.3)       | 7.4 (5.3-10.3)                      | 7.1 (4.9-10.2)                     | 0.049       |

Abbreviations: A/G, albumin to globulin; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLB, globulin; IQR, interquartile range.
DYNAMIC PROFILE OF LIVER FUNCTION INDICATORS IN PATIENTS WITH COVID-19

To determine the distribution and trajectory of parameters indicating liver functions in patients enrolled in the study, multiple results from liver function tests were recorded during hospitalization. Figure 2A displays the peak values of ALT, AST, ALP, and TBIL. Figure 2B depicts their distributions in patients with non-severe and severe COVID-19. ALT, AST, ALP, and TBIL levels were lower and less disperse in the non-severe cases. These levels increased and grew more disperse as the disease became more severe. Non-severe and severe case distribution had widest separation by AST level (Fig. 2B). LOESS models illustrated trajectory of ALT, AST, ALP, and TBIL in non-severe and severe patients during hospitalization (Fig. 2C). The models suggested a significant elevation of AST level upon admission and was maintained at higher levels in the severe group than the non-severe group. Although there was a significant difference in ALT between the non-severe group and the severe group, the magnitude of increase in ALT was not as dramatic as AST upon admission. However, it rapidly increased and surpassed the ULN value in the severe group. The level of ALT in severe group reached its peak within 10-15 days after admission. ALP level was higher in the severe group than the non-severe group. Both groups rose gradually during hospitalization but largely stayed in the normal range. The fluctuation in TBIL levels was mild in the non-severe and the severe groups. The dynamic changes in indicators suggested potential mechanisms of COVID-19-associated liver injury.

DETERMINING ASSOCIATIONS BETWEEN LIVER FUNCTION AND MORTALITY

Impaired liver function is closely related to mortality in patients with COVID-19. The associations of increased ALT, AST, ALP, and TBIL levels with all-cause mortality were assessed using mixed-effect Cox model. Hospital sites were treated as a random effect. Age, gender, and comorbidities were adjusted as confounders. Hazard ratios (HRs) for the associations between ALT, AST, ALP, and TBIL and all-cause mortality are provided in Table 2. The Kaplan–Meier survival curves with elevation in ALT, AST, ALP, and TBIL levels for all-cause mortality are illustrated in Fig. 3. Among these liver enzymes, elevated AST was associated with the highest mortality risk. Compared to the patients with AST in the normal range, all-cause mortality risk significantly increased 4.81-fold (95% confidence interval [CI], 3.38–6.86; \( P < 0.001 \)) in patients with AST between 40 U/L and 120 U/L and increased 14.87-fold (95% CI, 9.64–22.93; \( P < 0.001 \)) in patients with AST above 120 U/L after adjusting for age, gender, and comorbidities. Moreover, elevation of other enzymes and TBIL were also significantly associated with adverse outcomes of COVID-19 (Table 2 and Supporting Tables S4 and S5).

ASSOCIATIONS BETWEEN CLINICAL CHARACTERISTICS AND HOSPITAL MEDICATION WITH LIVER FUNCTIONS

The ordinal regression analysis revealed the effects of age, sex, and coexisting disease–adjusted baseline characteristics and hospital medication on peak ALT, AST, ALP, and TBIL levels in patients with COVID-19 from the longitudinal cohort (Table 3). Male gender, systemic corticosteroids application, lymphocyte count decrease, neutrophil count increase, and fever were factors positively associated with elevated ALT levels (Table 3). Use of antifungal drugs, lymphocyte count decrease, chronic liver disease, systemic corticosteroids use, and male gender were the leading factors positively associated with elevated AST levels. ALP levels were tightly associated with antifungal drug use, neutrophil counts increase, chronic liver disease, and male gender. Antifungal, antiviral, systemic corticosteroids use, and platelet count reduction were the
main factors positively correlated with increased TBIL levels. Neutrophil count increase, lymphocyte count decrease, and male gender were common factors positively associated with elevated ALT, AST, ALP, and TBIL levels during hospitalization (Table 3).
Discussion

Multiorgan injury, which significantly increases mortality, is often evident in patients with COVID-19. This study presents trajectories of liver enzyme levels during hospitalization and depicts their clinical significance in a multicenter retrospective cohort-derived data set of 5,771 individuals. Liver injury was mild and transient in non-severe patients. The major finding is that elevation of AST level was more frequent and significant than the increase of ALT in severe patients on hospital admission, and AST levels had the highest correlation with mortality compared with other indicators reflecting liver injury. This is contradictory to other hepatitis-induced liver injury. Increase of ALP was more significant toward the later phase of the disease but mainly stayed within the normal range. Elevated ALT and AST, the indicators of hepatocyte injury, was more common and severe in patients with COVID-19. Pathological analysis of liver tissue from a patient who died from COVID-19 failed to demonstrate cholangiocyte damage and viral infiltration in the liver. The elevations of lactate dehydrogenase and gamma-glutamyl transpeptidase, which also reflect bile duct injury, were not significant. Thus, the hypothesis of cholangiocytes mediating viral-associated injury needs further investigation.

In this study, we observed AST elevation upon admissions, followed by an increase in ALT. Previous studies also reported that AST increase is more frequent than ALT in severe patients with COVID-19 showed moderate microvascular steatosis and mild lobular and portal lesion. Liver damage may be associated with organ-specific immune response to coronavirus or secondary to hypoxemia, systemic inflammation response, and medication. A previous study showed that the angiotensin-converting enzyme 2 receptor expression is very low in hepatocytes and only expressed in cholangiocytes in the liver, suggesting that cholangiocytes might be a direct target for severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) invading the liver. However, in our study, ALP, an index of cholangiocytes injury, stayed primarily within the normal range during hospitalization. Elevation in ALT and AST, the indicators of hepatocyte injury, was more common and severe in patients with COVID-19. Pathological analysis of liver tissue from a patient who died from COVID-19 failed to demonstrate cholangiocyte damage and viral infiltration in the liver. The elevations of lactate dehydrogenase and gamma-glutamyl transpeptidase, which also reflect bile duct injury, were not significant. Thus, the hypothesis of cholangiocytes mediating viral-associated injury needs further investigation.

| Table 2. Associations Between Peak Values of Liver Enzymes and Mortality |
|-------------------|-------------------|-------------------|-------------------|
|                   | Mixed Cox Crude    |                  | Mixed Cox Age, Gender, Comorbidities (Adjusted) |
|                   | HR     | 95% CI  | PValue | HR     | 95% CI  | Pvalue |
| ALT               |         |         |        |         |         |        |
| <40 U/L           | Ref    |         |        | Ref    |         |        |
| 40-120 U/L        | 2.08   | (1.54, 2.81) | <0.001 | 1.43   | (1.04, 1.96) | 0.026 |
| >120 U/L          | 4.70   | (3.24, 6.81) | <0.001 | 3.56   | (2.37, 5.37) | <0.001 |
| AST               |         |         |        |         |         |        |
| <40 U/L           | Ref    |         |        | Ref    |         |        |
| 40-120 U/L        | 7.44   | (5.32, 10.41) | <0.001 | 4.81   | (3.38, 6.86) | <0.001 |
| >120 U/L          | 21.89  | (14.7, 32.59) | <0.001 | 14.87  | (9.64, 22.93) | <0.001 |
| ALP               |         |         |        |         |         |        |
| M: <125 U/L; F: <135 U/L | Ref |         |        | Ref    |         |        |
| M: 125-375 U/L; F: 135-405 U/L | 6.76  | (5.05, 9.06) | <0.001 | 4.24   | (3.12, 5.76) | <0.001 |
| M: >375 U/L; F: >405 U/L | 8.05  | (2.98, 21.77) | <0.001 | 5.86   | (2.03, 16.91) | 0.001 |
| TBIL              |         |         |        |         |         |        |
| <21 μmol/L        | Ref    |         |        | Ref    |         |        |
| 21-63 μmol/L      | 4.35   | (3.32, 5.68) | <0.001 | 3.28   | (2.47, 4.35) | <0.001 |
| >63 μmol/L        | 9.68   | (4.91, 19.07) | <0.001 | 7.98   | (3.88, 16.41) | <0.001 |

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; F, female; HR, hazard ratio; IQR, interquartile range; M, male; ref, reference; TBIL, total bilirubin.
upon admission. SARS-CoV-2 differs from other viruses, such as hepatitis B virus and SARS, in which ALT elevation is the primary manifestation of liver injury. Ordinal regression analysis also showed that AST elevation is positively correlated with the increase of neutrophil counts and the decrease of lymphocyte counts at baseline—pathological alterations that are proven indicators of disease severity. Early elevation in AST and its association with indicators for disease severity suggest that immune-mediated inflammation may play a critical role in liver impairment in severe patients with COVID-19. Mechanisms that mediate the early AST elevation in severe patients warrant further study.

The combination of antibiotics, antivirals, and systemic corticosteroids is used widely in COVID-19 treatment. Antifungal medication is more likely to be applied in weaker patients. In this study, use of antifungal drugs, antibiotics, antivirals, and systemic corticosteroids exhibited a positive correlation with elevated liver enzymes. Although these data could not

---

**FIG. 3.** Kaplan-Meier curves for cumulative probability of COVID-19 mortality during hospitalization in patients with different level of ALT (A), AST (B), ALP (C), and TBIL (D). ALT1: ALT < 40 U/L; ALT2: ALT = 40-120 U/L; ALT3: ALT > 120 U/L. AST1: AST < 40 U/L; AST2: AST = 40-120 U/L; AST3: AST > 120 U/L. ALP1: ALP < 125 U/L (males) and ALP < 135 U/L (females); ALP2: ALP = 125-375 U/L (males) and ALP = 135-405 U/L (females); ALP3: ALP > 375 U/L (males) and ALP > 405 U/L (females). TBIL1: TBIL < 21 μmol/L; TBIL2: TBIL = 21-63 μmol/L; TBIL3: TBIL > 63 μmol/L.
prove the causal effect of drugs on liver damage, drug hepatotoxicity during the treatment of coronavirus infection needs to be considered.

Due to this emergent situation, there is an insufficient report and diagnosis on chronic liver disease. Only 81 patients recorded a history of chronic liver disease (4 with nonalcoholic fatty liver disease and 77 with viral hepatitis), which are much lower than the prevalence in China.\(^{(20,21)}\) We are unable to assess whether coexistence of chronic liver comorbidities increases susceptibility to liver injury in SARS-CoV-2 infection. Previous studies have shown that SARS-CoV-2 may aggravate liver injury in patients with viral hepatitis.\(^{(22,23)}\) Therefore, liver injury in patients with chronic liver disease needs to be investigated and monitored.

Limitations exist in our research. This study was retrospective, and some cases did not have sufficient history of illness. The multiple tests for liver function were carried out at different time intervals for each patient. Bias may occur due to the increased number of tests in patients with liver dysfunction. Observational studies demonstrate association, not causation. Whether abnormal liver function is caused by SARS-CoV-2 or inflammation needs to be further investigated by direct clinical evidence. In conclusion, the dynamic patterns of liver injury indicators and their potential risk factors may provide an important explanation for the COVID-19-associated liver injury. Because the increase in liver injury indicators is strongly associated with the risk of mortality, these parameters, especially AST, may need to be monitored during hospitalization.

| Parameters                        | ALT OR (95% CI) PValue | AST OR (95% CI) PValue | ALP OR (95% CI) PValue | TBIL OR (95% CI) PValue |
|-----------------------------------|------------------------|------------------------|------------------------|------------------------|
| Age                               | 1.00 (0.99, 1.00) 0.627| 1.02 (1.01, 1.02) <0.001| 1.02 (1.00, 1.03) 0.006| 1.01 (1.00, 1.02) 0.111|
| Male gender                       | 2.36 (2.06, 2.69) <0.001| 1.60 (1.37, 1.86) <0.001| 2.00 (1.55, 2.58) <0.001| 1.52 (1.28, 1.81) <0.001|
| Heart rate                        | 1.00 (1.00, 1.01) 0.911| 1.00 (1.00, 1.01) 0.460| 1.01 (1.00, 1.02) 0.140| 0.99 (0.99, 1.00) 0.025|
| Respiratory rate                  | 1.01 (0.99, 1.03) 0.261| 1.02 (1.00, 1.04) 0.093| 1.03 (1.00, 1.06) 0.080| 1.04 (1.01, 1.06) 0.002|
| Fever                             | 1.47 (1.25, 1.72) <0.001| 1.51 (1.26, 1.81) <0.001| 1.01 (0.75, 1.36) 0.958| 1.11 (0.90, 1.35) 0.331|
| Cough                             | 1.02 (0.90, 1.16) 0.755| 0.98 (0.85, 1.14) 0.804| 0.90 (0.71, 1.15) 0.392| 0.99 (0.84, 1.18) 0.939|
| Dyspnea                           | 1.37 (1.18, 1.60) <0.001| 1.41 (1.19, 1.67) <0.001| 1.28 (0.98, 1.68) 0.071| 1.31 (1.08, 1.59) 0.007|
| Gastrointestinal symptoms         | 1.31 (1.10, 1.56) 0.002| 1.46 (1.20, 1.77) <0.001| 1.03 (0.73, 1.45) 0.869| 0.92 (0.72, 1.17) 0.484|
| Myalgia                           | 1.00 (0.83, 1.21) 0.996| 0.91 (0.73, 1.13) 0.399| 0.90 (0.61, 1.32) 0.584| 0.92 (0.72, 1.18) 0.526|
| COPD                              | 0.85 (0.40, 1.83) 0.683| 0.50 (0.20, 1.26) 0.142| 0.17 (0.02, 1.44) 0.104| 0.86 (0.34, 2.18) 0.748|
| Cardiovascular metabolic diseases | 0.96 (0.84, 1.11) 0.594| 0.98 (0.84, 1.15) 0.832| 0.17 (0.03, 1.19) 0.010| 0.86 (0.34, 2.18) 0.748|

Abbreviation: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; CI, confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio; TBIL, total bilirubin.
REFERENCES

1) Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-733.

2) World Health Organization. Coronavirus disease (COVID-2019) situation reports. In: Coronavirus Disease (COVID-2019) Situation Reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports; 2020. Published April 21, 2020. Accessed April 21, 2020.

3) Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-1720.

4) Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020 Apr 17. https://doi.org/10.1161/CIRCRESAHA.120.317134. [Epub ahead of print]

5) Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-422.

6) World Health Organization. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection is Suspected. World Health Organization; 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Published March 13, 2020. Accessed March 13, 2020.

7) Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1-138.

8) Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017;136:e137-e161.

9) Taylor FB Jr., Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH), et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-1330.

10) Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-481.

11) Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi 2020;49:E009 [Chinese].

12) Guan GW, Gao L, Wang JW, Wen XJ, Mao TH, Peng SW, et al. Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia. Zhonghua Gan Zang Bing Za Zhi 2020;28:E002 [Chinese].

13) Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-1069.

14) Liaw YF, Pao CC, Chu CM. Changes of serum HBV-DNA in relation to serum transaminase level during acute exacerbation in patients with chronic type B hepatitis. Liver 1988;8:231-235.

15) Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung VC, et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology 2004;39:302-310.

16) Wu KL, Lu SN, Changchien CS, Chiu KW, Kuo CH, Chuah SK, et al. Sequential changes of serum aminotransferase levels in patients with severe acute respiratory syndrome. Am J Trop Med Hyg 2004;71:125-128.

17) Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest 2020;130:2620-2629.

18) Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020 Mar 12. https://doi.org/10.1093/cid/ciaa248. [Epub ahead of print]

19) Qu H, Tong Z, Ma P, Hu M, Peng Z, Wu W, et al. Intensive care during the coronavirus epidemic. Intensive Care Med 2020;46:576-578.

20) Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Epidemiological feature of NAFLD from 1999 to 2018 in China. Hepatology 2020;71:1851-1864.

21) Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology 2019;70:1119-1133.

22) Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020;40:998-1004.

23) Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology 2020 Apr 16. https://doi.org/10.1002/hep.31281. [Epub ahead of print]

Author names in bold designate shared co-first authorship.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.31301/suppinfo.